Neuropeptide S (NPS) is the endogenous ligand of the neuropeptide S receptor (NPSR). NPS modulates several biological functions including anxiety, wakefulness, pain, and drug abuse. The aim of this study was the investigation of the pharmacological profile of NPSR using the dynamic mass redistribution (DMR) assay. DMR is a label-free assay that offers a holistic view of cellular responses after receptor activation. HEK293 cells stably transfected with the murine NPSR (HEK293 mNPSR ) have been used. To investigate the nature of the NPS-evoked DMR signaling, FR900359 (Gq inhibitor), pertussis toxin (Gi inhibitor), and rolipram (phosphodiesterase inhibitor) were used. To determine the pharmacology of NPSR, several selective ligands (agonists, partial agonists, antagonists) have been tested. NPS, through selective NPSR activation, evoked a robust DMR signal with potency in the nanomolar range.
| INTRODUCTION
Neuropeptide S (NPS, primary sequence in humans: SFRNGVGTG MKKTSFQRAKS) was identified in 2002 as the endogenous ligand of the previously orphaned G protein-coupled receptor (GPCR) GPR154, now referred to as neuropeptide S receptor (NPSR), using the reverse pharmacological approach. In 2004, an elegant study by Xu et al described, for the first time, some functional features of the NPS/ NPSR system. 1 NPSR is a GPCR showing moderate homology to other members of the GPCR family. 2 The in vitro pharmacology of the human and mouse NPSR has been mainly studied in heterologous expression systems. These studies showed that NPS increases both intracellular calcium levels and cAMP accumulation with EC 50 values in the low nanomolar range. This indicates that NPSR can signal via both Gq and Gs pathways to increase cellular excitability. 1, 3 In vivo, NPS has been shown to modulate several biological functions in rodents including stress, anxiety, social behavior, locomotor activity, wakefulness, food intake and gastrointestinal functions, memory processes, pain, and drug abuse (for reviews see 4 and 5).
Up to now, NPSR ligands have been characterized in vitro using single end-point assays, that is, calcium mobilization and cAMP accu- cytoskeletal remodeling, and cell adhesion changes. 8 
| Calcium mobilization assay
Cells were seeded at a density of 50 000 cells/well in 100 μL into 
| Data analysis and terminology
All data were analyzed using Graph Pad Prism 6.0 (La Jolla, CA, USA). Concentration-response curves were fitted using the four parameters log logistic equation. Data are expressed as mean ± SEM of n experiments performed in duplicate and were analyzed using one-or two-way analysis of variance (ANOVA) followed by Dunnett's or Tukey's test for multiple comparisons wherever appropriate.
Agonist potency was expressed as pEC 50 , which is the negative loga- Figure 1B . NPS was completely inactive in wild-type HEK293 cells (Table 1) . To analyze the biochemical nature of the NPS response, the peptide was tested in the absence and presence of the Figure 2A ), the Gi inhibitor PTX (100 ng mL −1 , Figure 2B ), and, with the aim to investigate the Gs dependent pathway, the phosphodiesterase inhibitor rolipram Figure 2C ). In HEK293 mNPSR cells, NPS (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) and NPS(1-10) produced a concentration-response curve with maximal effects similar to those eli- Figure 6 ).
| DMR effects of NPSR ligands
The pharmacological parameters of all the NPSR ligands evaluated in the DMR assay performed in HEK293 mNPSR cells have been summarized in Table 2 . In summary, NPS was the most potent NPSR 
| DISCUSSION AND CONCLUSION
Preclinical studies suggest NPSR as a promising therapeutic target for the treatment of anxiety disorders, cognitive deficits, pain, and Despite this NPSR signaling complexity, structure-activity relationship studies and drug discovery programs targeting NPSR have been conducted so far only with classical single end-point assays (for reviews see 4 and 5) . This approach may be reductionist and incomplete. Thus, in the present study, the NPS signal nature and pharmacological profile of a large panel of NPSR ligands have been investigated at the recombinant murine NPSR using the DMR assay.
This label-free approach offers the opportunity to comprehensively evaluate, in a noninvasive manner, the action of molecules after receptor binding, thus providing a global view on receptor-dependent cellular perturbations. NPS. 25 Different potencies in the DMR and calcium assay were ]NPS and NPS (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . In particular, NPS(1-10) displayed similar potency in calcium studies as NPS and was defined as the minimum NPS fragment able to maintain the same in vitro pharmacological activity as the full-length sequence. 23 In the present study, NPS(1-10) appeared 100-fold less potent than NPS. Of note, NPS(1-10) was recently defined by Liao et al as a calcium-biased NPSR agonist. 34 At present, we are unable to explain these differences in ligand potency between calcium mobilization and DMR assays. However, it should be underlined that these peptides were tested by Roth et al 23 on the human NPSR, thus speciesspecific receptor isoforms, rather than assay-related differences, may eventually explain these discrepancies.
Regarding NPSR agonists, another point that must be addressed is the pharmacological behavior of PWT1-NPS. This is a tetrabranched derivative of NPS that behaved in calcium experiments as an NPSR full agonist 3-fold more potent than the natural peptide.
The high in vitro potency of PWT1-NPS was associated with a high in vivo potency and long-lasting duration of action. 31 
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